General Information of the Compound
| Compound ID |
CP0416046
|
||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Compound Name |
4-{5-[(4-Fluoro-phenyl)-methanesulfonylamino-methyl]-[1,2,4]oxadiazol-3-yl}-N-{4-[2-((R)-2-hydroxy-2-pyridin-3-yl-ethylamino)-ethyl]-phenyl}-benzenesulfonamide
Show/Hide
|
||||||||||||||||||
| Structure |
|
||||||||||||||||||
| Formula |
C31H31FN6O6S2
|
||||||||||||||||||
| Molecular Weight |
666.757
|
||||||||||||||||||
| Canonical SMILES |
CS(=O)(=O)NC(c1nc(no1)-c1ccc(cc1)S(=O)(=O)Nc1ccc(CCNC[C@H](O)c2cccnc2)cc1)c1ccc(F)cc1
Show/Hide
|
||||||||||||||||||
| InChI |
InChI=1S/C31H31FN6O6S2/c1-45(40,41)38-29(22-6-10-25(32)11-7-22)31-35-30(36-44-31)23-8-14-27(15-9-23)46(42,43)37-26-12-4-21(5-13-26)16-18-34-20-28(39)24-3-2-17-33-19-24/h2-15,17,19,28-29,34,37-39H,16,18,20H2,1H3/t28-,29?/m0/s1
Show/Hide
|
||||||||||||||||||
| InChIKey |
RZSMMDOVVPJVHW-XLTVJXRZSA-N
|
||||||||||||||||||
| Physicochemical Property |
"RO5" indicates the cutoff set by lipinski's rule of five: (1) Molecular weight less than 500 Dalton; (2) xlogp less than 5; (3) No more than 5 hbonddonor (Hydrogen Bond Donor Count); (4) No more than 10 hbondacc (Hydrogen Bond Acceptor Count); (5) No more than 10 rotbonds (Rotatable Bond Count). Show/Hide
|
||||||||||||||||||
| Click to Show/Hide the External Link(s) of This Compound | |||||||||||||||||||
| PubChem ID | |||||||||||||||||||
| ChEMBL ID | |||||||||||||||||||
Map of Molecular Bioactivity Related to the Compound
|
Map of Molecular Bioactivity Related to the Compound Compound Cell Line Protein Bioactivity Value: <= 0.1 μM > 0.1 μM and <= 10 μM > 10 μM Imprecise Activity |
|
|---|
Table of Molecular Bioactivities Related to the Compound
Protein ID: PT01179, Beta-1 adrenergic receptor
Protein ID: PT01494, Beta-2 adrenergic receptor
Protein ID: PT01493, Beta-3 adrenergic receptor